Share

Kiora Pharmaceuticals Inc. - news published 142 - readings 1.622

BACK
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 March 25, 2025 7:00 am EDT Download as PDF Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today ann ...

Continue reading
25.03.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-term Investments Expected to Fund Operations into 2027 (Form 8-K)

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-term Investments Expected to Fund Operations into 2027 Encinitas, California - March 25, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on i ...

Continue reading
25.03.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 25, 2025 Commission File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 98-0443284 (State or other jurisdiction of incorporati ...

Continue reading
25.03.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting March 12, 2025 7:00 am EDT Download as PDF Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinica ...

Continue reading
12.03.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Secures U.S. Composition of Matter Patent Expanding Protection of Its Anti Inflammatory Compound KIO 104

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 February 13, 2025 7:00 am EST Download as PDF Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent ( ...

Continue reading
13.02.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema February 11, 2025 6:45 am EST Download as PDF Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initia ...

Continue reading
11.02.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8 K

kprx-20250110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2025 KIORA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora ...

Continue reading
15.01.2025
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Form 8 K

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California - November 8, 2024 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal d ...

Continue reading
08.11.2024
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

kprx-20240930 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Continue reading
08.11.2024
Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS 2, a Phase 2 Clinical Trial of KIO 301 for the Treatment of Retinitis Pigmentosa Form 8 K

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California - October 29,2024 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical tri ...

Continue reading
29.10.2024